Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04711109 · ClinicalTrials.gov registry record · Phase 3
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
A Phase 3 study of Breast Cancer and Neoplasms, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT04711109 is a Phase 3 study of Breast Cancer and Neoplasms that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 300 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04711109, a Phase 3 study of Breast Cancer and Neoplasms, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER Quality-of-Life Assessment
- DRUG Denosumab
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers-Aurora - Aurora
- UCHealth University of Colorado Hospital - Aurora
- Rocky Mountain Cancer Centers-Boulder - Boulder
- Rocky Mountain Cancer Centers - Centennial - Centennial
- Rocky Mountain Cancer Centers-Midtown - Denver
- Rocky Mountain Cancer Centers-Rose - Denver
- Mountain Blue Cancer Care Center - Swedish - Englewood
- Rocky Mountain Cancer Centers - Swedish - Englewood
- Rocky Mountain Cancer Centers-Littleton - Littleton
- Rocky Mountain Cancer Centers-Sky Ridge - Lone Tree
Illinois
- Northwestern University - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- NorthShore University HealthSystem-Highland Park Hospital - Highland Park
- Carle Cancer Center - Urbana
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UCSF Medical Center-Mount Zion - San Francisco
Kansas
- University of Kansas Hospital-Indian Creek Campus - Overland Park
- University of Kansas Hospital-Westwood Cancer Center - Westwood
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2033-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04711109
The ClinicalTrials.gov registry entry for NCT04711109 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04711109 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT04711109 about?
NCT04711109 is a clinical study titled "Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation". This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibo...
What is the current status of trial NCT04711109?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2023-02-14. Estimated completion is 2033-12.
What conditions does trial NCT04711109 study?
This clinical trial studies the following conditions: Breast Cancer, Neoplasms, Breast Carcinoma, Breast Neoplasms, BRCA1 Mutation.
What interventions are being tested in trial NCT04711109?
The interventions under investigation include: Placebo (DRUG), Quality-of-Life Assessment (OTHER), Denosumab (DRUG).
Who is sponsoring clinical trial NCT04711109?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04711109 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.